# Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

> **NCT02639559** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 50 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Acute Lymphoblastic Leukemia
- Chronic Myelogenous Leukemia
- Non-Hodgkin's Lymphoma
- Non-Hodgkin Lymphoma
- Hodgkin Disease
- Hodgkins Disease
- Hodgkin's Disease
- Multiple Myeloma
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm

## Interventions

- **DRUG:** BL-8040
- **PROCEDURE:** Leukapheresis
- **PROCEDURE:** Hematopoietic cell transplant

## Key facts

- **NCT ID:** NCT02639559
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-31
- **Primary completion:** 2018-04-12
- **Final completion:** 2023-04-07
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02639559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02639559, "Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02639559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*